NCT03737994 2026-03-18
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT04318938 2026-03-02
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT05721950 2026-02-18
Brilliant
Takeda
Active not recruiting
NCT04223596 2026-02-04
CUBIK
Fundación GECP
Phase 2 Active not recruiting
NCT04374305 2026-01-12
INTUITT-NF2
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04925609 2025-12-05
Briga-PED
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05200481 2025-11-17
MP-ALK
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Active not recruiting
NCT03707938 2025-11-03
Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04227028 2025-09-16
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03596866 2025-09-12
ALTA-3
Takeda
Phase 3 Completed
NCT03535740 2025-07-31
ALTA-2
Takeda
Phase 2 Completed
NCT06522360 2025-04-24
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed